Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

M. A. Jacobson, J. Gallant, L. H. Wang, D. Coakley, S. Weller, D. Gary, L. Squires, M. L. Smiley, M. R. Blum, J. Feinberg

Research output: Contribution to journalArticlepeer-review

Abstract

Valaciclovir, the L-valyl ester of acyclovir, is rapidly and extensively converted in humans to acyclovir after oral administration by first-pass metabolism. A phase I study was conducted in two cohorts of volunteers with advanced human immunodeficiency virus (HIV) disease (absolute CD4 lymphocyte count of

Original languageEnglish (US)
Pages (from-to)1534-1540
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume38
Issue number7
StatePublished - 1994
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease'. Together they form a unique fingerprint.

Cite this